Merge PR #1349: extract openevidence clinical AI growth

domains/health/OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md

@@ -17,6 +17,12 @@ What makes this significant is the adoption speed. Reaching 40% of US physicians
 
 The incumbent response is UpToDate ExpertAI (Wolters Kluwer, Q4 2025), leveraging its trusted brand and install base. The competitive dynamic -- startup vs incumbent in clinical decision support -- will determine whether AI clinical knowledge becomes a winner-take-all market or fragments.
 
+
+### Additional Evidence (extend)
+*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-18*
+
+OpenEvidence scale as of January 2026: 20M clinical consultations/month (up from 8.5M in 2025, representing 2,000%+ YoY growth), valuation increased from $3.5B to $12B in months, reached 1M consultations in a single day (March 10, 2026 milestone), used across 10,000+ hospitals. First AI to score 100% on all parts of USMLE. Despite this scale, 44% of physicians remain concerned about accuracy/misinformation and 19% about lack of oversight/explainability—trust barriers persist even among heavy users.
+
 ---
 
 Relevant Notes:

domains/health/healthcare AI funding follows a winner-take-most pattern with category leaders absorbing capital at unprecedented velocity while 35 percent of deals are flat or down rounds.md

@@ -25,6 +25,12 @@ The emerging consensus: healthcare AI is a platform shift, not a bubble, but the
 
 Abridge raised $300M Series E at $5B valuation and Ambiance raised $243M Series C at $1.04B valuation by early 2026, demonstrating the capital concentration in category leaders. Function Health's $300M Series C at $2.2B valuation further confirms winner-take-most dynamics in health AI.
 
+
+### Additional Evidence (confirm)
+*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-18*
+
+OpenEvidence valuation trajectory demonstrates winner-take-most dynamics: $3.5B → $6B → $12B in under 12 months, with $250M Series D led by Thrive Capital and DST Global. This 3.4x valuation increase in months while 35% of healthcare AI deals are flat/down rounds confirms capital concentration in category leaders.
+
 ---
 
 Relevant Notes:

domains/health/medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md

@@ -17,6 +17,12 @@ A deeper finding from a Stanford/Harvard study challenges even the "similar accu
 
 The implication for AI deployment strategy: the highest-value clinical AI applications are not diagnostic augmentation but workflow automation (ambient documentation, administrative burden reduction) and safety netting (AI triage catching missed findings). The centaur model may still apply to medicine, but the interaction design must prevent physicians from overriding AI on tasks where AI demonstrably outperforms -- a politically and ethically charged constraint.
 
+
+### Additional Evidence (challenge)
+*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-18*
+
+OpenEvidence achieved 100% USMLE score (first AI in history) and is now deployed at 20M consultations/month across 40%+ of US physicians, creating the first large-scale empirical test of whether benchmark performance translates to population health outcomes. The absence of published outcomes data at this deployment scale represents a critical evidence gap—if benchmark performance doesn't translate to clinical impact, we should see evidence of that at 20M monthly consultations.
+
 ---
 
 Relevant Notes:

inbox/queue/2026-01-01-openevidence-clinical-ai-growth-12b-valuation.md

@@ -7,9 +7,13 @@ date: 2026-01-01
 domain: health
 secondary_domains: [ai-alignment]
 format: company-announcement
-status: unprocessed
+status: enrichment
 priority: medium
 tags: [openevidence, clinical-ai, decision-support, physician-adoption, clinical-decision-support, health-ai, trust]
+processed_by: vida
+processed_date: 2026-03-18
+enrichments_applied: ["OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md", "medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md", "healthcare AI funding follows a winner-take-most pattern with category leaders absorbing capital at unprecedented velocity while 35 percent of deals are flat or down rounds.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -68,3 +72,15 @@ This creates a two-track clinical AI story: (1) Abridge/ambient scribes for docu
 PRIMARY CONNECTION: [[OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years]]
 WHY ARCHIVED: Significant scale update — the existing claim understates 2026 metrics by an order of magnitude. Also: USMLE 100% creates the benchmark vs. outcomes tension in practice, not theory.
 EXTRACTION HINT: Update the existing claim with scale metrics, but flag the benchmark-to-outcomes translation tension as a challenge to both the OpenEvidence claim and the benchmark performance claim
+
+
+## Key Facts
+- OpenEvidence reached 8.5M clinical consultations/month in 2025
+- OpenEvidence reached 20M clinical consultations/month by January 2026
+- OpenEvidence valuation: $3.5B → $6B → $12B in under 12 months
+- OpenEvidence Series D: $250M led by Thrive Capital and DST Global (January 2026)
+- OpenEvidence first AI to score 100% on USMLE (all parts)
+- OpenEvidence used across 10,000+ hospitals and medical centers
+- March 10, 2026: OpenEvidence reached 1M consultations in one day
+- 44% of physicians concerned about OpenEvidence accuracy/misinformation risk
+- 19% of physicians concerned about lack of physician oversight/explainability